Back to Search
Start Over
Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?
- Source :
- European journal of drug metabolism and pharmacokinetics. 46(4)
- Publication Year :
- 2021
-
Abstract
- Morbidity and mortality from serious infections are common in intensive care units (ICUs). The appropriateness of the antibiotic treatment is essential to combat sepsis. We aimed to evaluate pharmacokinetic/pharmacodynamic target attainment of meropenem and piperacillin/tazobactam administered at standard total daily dose as continuous infusion in critically ill patients without renal dysfunction and to identify risk factors of non-pharmacokinetic/pharmacodynamic target attainment.We included 118 patients (149 concentrations), 47% had microorganism isolation. Minimum inhibitory concentration (MIC) [median (interquartile range, IQR) values in isolated pathogens were: meropenem: 0.05 (0.02-0.12) mg/l; piperacillin: 3 (1-4) mg/l]. Pharmacokinetic/pharmacodynamic target attainments (100%fCStandard total daily dose of meropenem allowed achieving pharmacokinetic/pharmacodynamic target attainments in ICU patients without renal dysfunction. Higher doses of piperacillin/tazobactam would be needed to cover microorganisms with MIC8 mg/l. CrCL was the most powerful factor predictive of fC
Details
- ISSN :
- 21070180
- Volume :
- 46
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- European journal of drug metabolism and pharmacokinetics
- Accession number :
- edsair.pmid..........2b63ba59d601568648b769ef4170d9cc